• Clinically confirmed diagnosis of recurrent respiratory papillomatosis.

• Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required.

• Human papilloma virus (HPV)6+ RRP in larynx

• ECOG (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I).

• The following laboratory values obtained ≤ 28 days prior to apheresis.

‣ Absolute neutrophil count (ANC) ≥1.0 x 109 /L

⁃ Platelet count (PLT) ≥ 75 x 109 /L

⁃ Hemoglobin ≥ 8.5 g/dL

⁃ Lymphocytes ≥ 0.3 x 109 /L

⁃ Total bilirubin ≤ 2 x upper limit of normal (ULN), unless patient has a documented history of Gilbert's disease, then Direct bilirubin ≤1.0 mg/dL.

⁃ Aspartate transaminase (AST) ≤ 3 x ULN

⁃ Creatinine ≤ 2.0 mg/dL

⁃ Monocytes ≥ 0.25 x 109 /L

• Able to provide informed written consent.

• Willingness to return to Mayo Clinic Arizona for follow-up appointments

• Willingness to provide blood samples for immune assessment and other tests

• Willingness to provide papilloma tissues that will be surgically removed

• Agree that during the trial, male participants will not father a child and female participants cannot be or become pregnant if they are of child-bearing potential.

• Subjects must fulfill one of the following conditions:

‣ Agree to use one highly effective or combined contraceptive method that results in a failure rate of methods must always be supplemented with the use of spermicide.

⁃ Be surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females).

⁃ Be of non-childbearing potential (≥12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone \[FSH\], if not on hormone replacement).